HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,489,828 | +8.1% | 2,787,349 | +2.1% | 0.01% | +8.3% |
| Q2 2023 | $98,480,801 | -2.0% | 2,730,268 | +3.8% | 0.01% | -7.7% |
| Q1 2023 | $100,492,709 | +70121.1% | 2,631,387 | +4.6% | 0.01% | -35.0% |
| Q4 2022 | $143,109 | -99.9% | 2,515,097 | +1.5% | 0.02% | +33.3% |
| Q3 2022 | $97,935,000 | -8.9% | 2,476,864 | +1.4% | 0.02% | -6.2% |
| Q2 2022 | $107,478,000 | +7.5% | 2,442,698 | -2.5% | 0.02% | +33.3% |
| Q1 2022 | $99,960,000 | +0.5% | 2,506,534 | +1.3% | 0.01% | 0.0% |
| Q4 2021 | $99,502,000 | -0.5% | 2,474,566 | +0.6% | 0.01% | -7.7% |
| Q3 2021 | $100,031,000 | -10.0% | 2,458,973 | +0.5% | 0.01% | -13.3% |
| Q2 2021 | $111,101,000 | +17.5% | 2,446,622 | +7.9% | 0.02% | +7.1% |
| Q1 2021 | $94,521,000 | +4.0% | 2,267,258 | +6.6% | 0.01% | -6.7% |
| Q4 2020 | $90,878,000 | +69.3% | 2,127,800 | +4.1% | 0.02% | +36.4% |
| Q3 2020 | $53,690,000 | +4.8% | 2,043,024 | +6.9% | 0.01% | 0.0% |
| Q2 2020 | $51,216,000 | +51.2% | 1,910,341 | +1.4% | 0.01% | +22.2% |
| Q1 2020 | $33,883,000 | -49.3% | 1,883,508 | -50.0% | 0.01% | +28.6% |
| Q4 2019 | $66,836,000 | +136.2% | 3,769,666 | +106.6% | 0.01% | 0.0% |
| Q3 2019 | $28,297,000 | -10.2% | 1,824,500 | -0.5% | 0.01% | -12.5% |
| Q2 2019 | $31,505,000 | +18.7% | 1,833,838 | +11.3% | 0.01% | +14.3% |
| Q1 2019 | $26,538,000 | -40.4% | 1,648,355 | -45.8% | 0.01% | 0.0% |
| Q4 2018 | $44,494,000 | +69.6% | 3,041,314 | +110.6% | 0.01% | 0.0% |
| Q3 2018 | $26,234,000 | +10.8% | 1,443,904 | +2.9% | 0.01% | 0.0% |
| Q2 2018 | $23,675,000 | -5.1% | 1,403,421 | +10.2% | 0.01% | -12.5% |
| Q1 2018 | $24,958,000 | -1.5% | 1,274,018 | +1.8% | 0.01% | -11.1% |
| Q4 2017 | $25,348,000 | +26.6% | 1,251,161 | +8.5% | 0.01% | +28.6% |
| Q3 2017 | $20,028,000 | +35.2% | 1,153,116 | -0.2% | 0.01% | +16.7% |
| Q2 2017 | $14,816,000 | +18.8% | 1,155,799 | +20.1% | 0.01% | +20.0% |
| Q1 2017 | $12,473,000 | +39.6% | 962,500 | +6.4% | 0.01% | +25.0% |
| Q4 2016 | $8,934,000 | -12.4% | 904,285 | +7.1% | 0.00% | -20.0% |
| Q3 2016 | $10,203,000 | +52.3% | 844,687 | +8.8% | 0.01% | +25.0% |
| Q2 2016 | $6,698,000 | -5.0% | 776,138 | +4.3% | 0.00% | 0.0% |
| Q1 2016 | $7,048,000 | -45.6% | 744,320 | -0.4% | 0.00% | -42.9% |
| Q4 2015 | $12,952,000 | +37.9% | 747,424 | +6.9% | 0.01% | +16.7% |
| Q3 2015 | $9,393,000 | -38.8% | 699,444 | +2.8% | 0.01% | -33.3% |
| Q2 2015 | $15,356,000 | +63.5% | 680,137 | +3.4% | 0.01% | +80.0% |
| Q1 2015 | $9,391,000 | +66.6% | 657,669 | +12.5% | 0.01% | +66.7% |
| Q4 2014 | $5,638,000 | +5.9% | 584,391 | -0.1% | 0.00% | 0.0% |
| Q3 2014 | $5,324,000 | -3.9% | 585,204 | +4.3% | 0.00% | -25.0% |
| Q2 2014 | $5,542,000 | -20.6% | 561,019 | +2.1% | 0.00% | -20.0% |
| Q1 2014 | $6,978,000 | -3.7% | 549,479 | +13.7% | 0.01% | 0.0% |
| Q4 2013 | $7,244,000 | +60.5% | 483,283 | +18.3% | 0.01% | +25.0% |
| Q3 2013 | $4,512,000 | +56.8% | 408,684 | +12.8% | 0.00% | +33.3% |
| Q2 2013 | $2,877,000 | – | 362,303 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |